Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2017-01

AUTHORS

Surasak Phuphanich, Jeffrey Raizer, Marc Chamberlain, Paola Canelos, Rajesh Narwal, Shengyan Hong, Robert Miday, Minal Nade, Kevin Laubscher

ABSTRACT

MEDI-575, an immunoglobulin G2κ monoclonal antibody, selectively binds to platelet-derived growth factor-α receptor (PDGFR-α) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25 mg/kg intravenously over 60 min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability. PDGFR-α expression was evaluated by immunohistochemistry. Fifty-six patients were enrolled; median age was 56.5 years (range 23-79), 66 % were male, and 66 % were aged ≥65 years. PFS-6 was 15.4 % [90 % confidence interval (CI) 8.1-24.9]. No complete or partial responses were observed; 23 (41.1 %) patients had stable disease as best response. Median PFS was 1.4 months (90 % CI 1.4, 1.8); median OS was 9.7 months (90 % CI 6.5, 11.8). The most common treatment-related adverse events (AEs) were diarrhea (16 %), nausea (13 %), and fatigue (13 %). Twelve (21 %) patients reported grade ≥3 AEs, with hydrocephalus (n = 3), dysphagia (n = 2), and convulsion (n = 2) reported in more than 1 patient. Two patients had treatment-related Grade ≥3 AEs of decreased lymphocyte count and asthenia (n = 1 each). Seven patients (13 %) discontinued MEDI-575 owing to AEs. Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblastoma. More... »

PAGES

185-191

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11060-016-2287-6

DOI

http://dx.doi.org/10.1007/s11060-016-2287-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1008212688

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27844311


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Immunological", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glioblastoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Magnetic Resonance Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Barrow Neurological Institute", 
          "id": "https://www.grid.ac/institutes/grid.427785.b", 
          "name": [
            "Johnnie L. Cochran Jr. Brain Tumor Center, Cedars-Sinai Medical Center, 127 South San Vicente Blvd, Los Angeles, CA, USA", 
            "Department of Neurology, Division of Neuro-Oncology, Barrow Neurological Institute, 240 West Thomas Road, Suite 400, 85013, Phoenix, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Phuphanich", 
        "givenName": "Surasak", 
        "id": "sg:person.01346246457.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346246457.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Northwestern University", 
          "id": "https://www.grid.ac/institutes/grid.16753.36", 
          "name": [
            "Northwestern Brain Tumor Institute, Northwestern University, 675 N. St. Clair, 60611, Chicago, IL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raizer", 
        "givenName": "Jeffrey", 
        "id": "sg:person.010677556177.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010677556177.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Washington", 
          "id": "https://www.grid.ac/institutes/grid.34477.33", 
          "name": [
            "University of Washington, 1959 NE Pacific St., 8th Floor, 98195, Seattle, WA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chamberlain", 
        "givenName": "Marc", 
        "id": "sg:person.01326261166.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, 1 MedImmune Way, 20878, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Canelos", 
        "givenName": "Paola", 
        "id": "sg:person.01070375330.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070375330.62"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, 1 MedImmune Way, 20878, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narwal", 
        "givenName": "Rajesh", 
        "id": "sg:person.0664155437.21", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664155437.21"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, 1 MedImmune Way, 20878, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hong", 
        "givenName": "Shengyan", 
        "id": "sg:person.0767403115.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767403115.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, 1 MedImmune Way, 20878, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miday", 
        "givenName": "Robert", 
        "id": "sg:person.010544200534.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010544200534.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, 1 MedImmune Way, 20878, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nade", 
        "givenName": "Minal", 
        "id": "sg:person.010336770753.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010336770753.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418152.b", 
          "name": [
            "MedImmune, 1 MedImmune Way, 20878, Gaithersburg, MD, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Laubscher", 
        "givenName": "Kevin", 
        "id": "sg:person.014305467411.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014305467411.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.ctrv.2012.05.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001159071"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(09)70025-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002463620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/not151", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003959313"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-13-0028", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004343764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605411", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013740225", 
          "https://doi.org/10.1038/sj.bjc.6605411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605411", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013740225", 
          "https://doi.org/10.1038/sj.bjc.6605411"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0007752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018946723"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9976-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019029141", 
          "https://doi.org/10.1007/s11060-009-9976-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9976-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019029141", 
          "https://doi.org/10.1007/s11060-009-9976-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/mabs.3.2.14239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020539044"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6605225", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030833831", 
          "https://doi.org/10.1038/sj.bjc.6605225"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2567-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032526725", 
          "https://doi.org/10.1007/s00280-014-2567-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-014-2567-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032526725", 
          "https://doi.org/10.1007/s00280-014-2567-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9957-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040541619", 
          "https://doi.org/10.1007/s11060-009-9957-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11060-009-9957-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040541619", 
          "https://doi.org/10.1007/s11060-009-9957-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/03009734.2014.970304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041806583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.8721", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042965400"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2009.26.3541", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043187529"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/mol.112.084079", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048097764"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1101/gad.1972310", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050112647"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0b013e31820f2d94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064355987"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0b013e31820f2d94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064355987"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1212/wnl.0b013e31820f2d94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064355987"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1999.17.8.2572", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074549881"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075516477", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075562439", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-01", 
    "datePublishedReg": "2017-01-01", 
    "description": "MEDI-575, an immunoglobulin G2\u03ba monoclonal antibody, selectively binds to platelet-derived growth factor-\u03b1 receptor (PDGFR-\u03b1) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25\u00a0mg/kg intravenously over 60\u00a0min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability. PDGFR-\u03b1 expression was evaluated by immunohistochemistry. Fifty-six patients were enrolled; median age was 56.5 years (range 23-79), 66\u2009% were male, and 66\u2009% were aged \u226565 years. PFS-6 was 15.4\u2009% [90\u2009% confidence interval (CI) 8.1-24.9]. No complete or partial responses were observed; 23 (41.1\u2009%) patients had stable disease as best response. Median PFS was 1.4 months (90\u2009% CI 1.4, 1.8); median OS was 9.7 months (90\u2009% CI 6.5, 11.8). The most common treatment-related adverse events (AEs) were diarrhea (16\u2009%), nausea (13\u2009%), and fatigue (13\u2009%). Twelve (21\u2009%) patients reported grade \u22653 AEs, with hydrocephalus (n\u2009=\u20093), dysphagia (n\u2009=\u20092), and convulsion (n\u2009=\u20092) reported in more than 1 patient. Two patients had treatment-related Grade \u22653 AEs of decreased lymphocyte count and asthenia (n\u2009=\u20091 each). Seven patients (13\u2009%) discontinued MEDI-575 owing to AEs. Labeling of PDGFR\u03b1 in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblastoma.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s11060-016-2287-6", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094205", 
        "issn": [
          "0167-594X", 
          "1573-7373"
        ], 
        "name": "Journal of Neuro-Oncology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "131"
      }
    ], 
    "name": "Phase II study of MEDI-575, an anti-platelet-derived growth factor-\u03b1 antibody, in patients with recurrent glioblastoma", 
    "pagination": "185-191", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "27205036ef571d57ef7b54e0c96f09b286cebf28fb28ba8f87545b6fa94381d5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27844311"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309335"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11060-016-2287-6"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1008212688"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11060-016-2287-6", 
      "https://app.dimensions.ai/details/publication/pub.1008212688"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87117_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs11060-016-2287-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2287-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2287-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2287-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11060-016-2287-6'


 

This table displays all metadata directly associated to this object as RDF triples.

262 TRIPLES      21 PREDICATES      65 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11060-016-2287-6 schema:about N07ae6dab512a48e297a40a92f60a6565
2 N1577289f23e84fce98569e29c33ff83e
3 N16b93b2a3d2946ffae7e6c3696d1ad9b
4 N2156c28e11444134bfebca5da3b8e049
5 N2353bb23ca3646cf8388f089e632ecfc
6 N32e2bc7b9cc44788a82fc99d32d285d8
7 N33186bb6a00b4b64a12b178fd0f128c8
8 N3fe8cd11cd8b40efbe2c331b7828ee99
9 N7bcd40a156be4819a83efbca50c78f80
10 N80ab2d8f31b04a13aa6d19ed5bd70f6d
11 N846d6dd56f124a5995b85e7a4dc22345
12 N85c85fd9deb54d078499aa209edc9727
13 Ncd18a4907f854f8dbf043819a5ce14a8
14 Nd14c08c66e61441aa6c0d1bf4ef830ab
15 Ndf609ccb9c98467196d9035840a8023d
16 Nf4418c2cd2b74d5aafaee4428b4a9184
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author N8168985e03674c8e9a5421499bd8d7fa
20 schema:citation sg:pub.10.1007/s00280-014-2567-9
21 sg:pub.10.1007/s11060-009-9957-6
22 sg:pub.10.1007/s11060-009-9976-3
23 sg:pub.10.1038/sj.bjc.6605225
24 sg:pub.10.1038/sj.bjc.6605411
25 https://app.dimensions.ai/details/publication/pub.1075516477
26 https://app.dimensions.ai/details/publication/pub.1075562439
27 https://doi.org/10.1016/j.ctrv.2012.05.006
28 https://doi.org/10.1016/s1470-2045(09)70025-7
29 https://doi.org/10.1093/neuonc/not151
30 https://doi.org/10.1101/gad.1972310
31 https://doi.org/10.1124/mol.112.084079
32 https://doi.org/10.1158/2326-6066.cir-13-0028
33 https://doi.org/10.1200/jco.1999.17.8.2572
34 https://doi.org/10.1200/jco.2008.19.8721
35 https://doi.org/10.1200/jco.2009.26.3541
36 https://doi.org/10.1212/wnl.0b013e31820f2d94
37 https://doi.org/10.1371/journal.pone.0007752
38 https://doi.org/10.3109/03009734.2014.970304
39 https://doi.org/10.4161/mabs.3.2.14239
40 schema:datePublished 2017-01
41 schema:datePublishedReg 2017-01-01
42 schema:description MEDI-575, an immunoglobulin G2κ monoclonal antibody, selectively binds to platelet-derived growth factor-α receptor (PDGFR-α) with high specificity. This multicenter, single-arm, open-label, phase II study evaluated the efficacy and safety of MEDI-575 in patients with recurrent glioblastoma. Adults with first recurrence of glioblastoma following surgery, temozolomide, and radiation received MEDI-575 25 mg/kg intravenously over 60 min every 21 days until disease progression or unacceptable toxicity. Six-month progression-free survival rate (PFS-6) was the primary end point; secondary measures included response rate, overall survival (OS), and safety/tolerability. PDGFR-α expression was evaluated by immunohistochemistry. Fifty-six patients were enrolled; median age was 56.5 years (range 23-79), 66 % were male, and 66 % were aged ≥65 years. PFS-6 was 15.4 % [90 % confidence interval (CI) 8.1-24.9]. No complete or partial responses were observed; 23 (41.1 %) patients had stable disease as best response. Median PFS was 1.4 months (90 % CI 1.4, 1.8); median OS was 9.7 months (90 % CI 6.5, 11.8). The most common treatment-related adverse events (AEs) were diarrhea (16 %), nausea (13 %), and fatigue (13 %). Twelve (21 %) patients reported grade ≥3 AEs, with hydrocephalus (n = 3), dysphagia (n = 2), and convulsion (n = 2) reported in more than 1 patient. Two patients had treatment-related Grade ≥3 AEs of decreased lymphocyte count and asthenia (n = 1 each). Seven patients (13 %) discontinued MEDI-575 owing to AEs. Labeling of PDGFRα in glioblastoma cells and tumor-associated stromal cells was highly variable, with no correlation with PFS. MEDI-575, although well tolerated, had limited clinical activity in recurrent glioblastoma.
43 schema:genre research_article
44 schema:inLanguage en
45 schema:isAccessibleForFree false
46 schema:isPartOf Nb20d5fed7e614ffbb6187dbd8b284b1d
47 Nc043c3af1d83423bac39c0d8389ca4c0
48 sg:journal.1094205
49 schema:name Phase II study of MEDI-575, an anti-platelet-derived growth factor-α antibody, in patients with recurrent glioblastoma
50 schema:pagination 185-191
51 schema:productId N17e10d3c43c247c899523ea9c8223299
52 N2f262911d590401ba6e42e6124377a33
53 N95846e096d3845e59f110391cecc8188
54 Nabeca82624de4d11a42cd3abca735a7a
55 Nf45086036bce4b3f85cc6587c2d7be17
56 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008212688
57 https://doi.org/10.1007/s11060-016-2287-6
58 schema:sdDatePublished 2019-04-11T12:27
59 schema:sdLicense https://scigraph.springernature.com/explorer/license/
60 schema:sdPublisher Nba3b3106819b4de5acf7b3083266fdc2
61 schema:url https://link.springer.com/10.1007%2Fs11060-016-2287-6
62 sgo:license sg:explorer/license/
63 sgo:sdDataset articles
64 rdf:type schema:ScholarlyArticle
65 N07ae6dab512a48e297a40a92f60a6565 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Middle Aged
67 rdf:type schema:DefinedTerm
68 N1577289f23e84fce98569e29c33ff83e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Brain Neoplasms
70 rdf:type schema:DefinedTerm
71 N16b93b2a3d2946ffae7e6c3696d1ad9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
72 schema:name Adult
73 rdf:type schema:DefinedTerm
74 N17e10d3c43c247c899523ea9c8223299 schema:name readcube_id
75 schema:value 27205036ef571d57ef7b54e0c96f09b286cebf28fb28ba8f87545b6fa94381d5
76 rdf:type schema:PropertyValue
77 N2156c28e11444134bfebca5da3b8e049 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Magnetic Resonance Imaging
79 rdf:type schema:DefinedTerm
80 N2353bb23ca3646cf8388f089e632ecfc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Male
82 rdf:type schema:DefinedTerm
83 N2f262911d590401ba6e42e6124377a33 schema:name dimensions_id
84 schema:value pub.1008212688
85 rdf:type schema:PropertyValue
86 N32e2bc7b9cc44788a82fc99d32d285d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Neoplasm Recurrence, Local
88 rdf:type schema:DefinedTerm
89 N33186bb6a00b4b64a12b178fd0f128c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Glioblastoma
91 rdf:type schema:DefinedTerm
92 N368b83474971493a9babf14adc5b7844 rdf:first sg:person.010544200534.01
93 rdf:rest Nc5f4f955a8d04dc398e837b36d110f49
94 N3fe8cd11cd8b40efbe2c331b7828ee99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Humans
96 rdf:type schema:DefinedTerm
97 N43a1ceecf43a48a487e4ecda5e0fbf38 rdf:first sg:person.010677556177.51
98 rdf:rest N7ea2ddafa8f247e98838fa77ffc7283b
99 N574629a07b2e46929c312e65c5558f8f rdf:first sg:person.01070375330.62
100 rdf:rest N99bd846e3a3040f9b7d13c804e927ac1
101 N7bcd40a156be4819a83efbca50c78f80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name United States
103 rdf:type schema:DefinedTerm
104 N7ea2ddafa8f247e98838fa77ffc7283b rdf:first sg:person.01326261166.36
105 rdf:rest N574629a07b2e46929c312e65c5558f8f
106 N80ab2d8f31b04a13aa6d19ed5bd70f6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Treatment Outcome
108 rdf:type schema:DefinedTerm
109 N8168985e03674c8e9a5421499bd8d7fa rdf:first sg:person.01346246457.67
110 rdf:rest N43a1ceecf43a48a487e4ecda5e0fbf38
111 N846d6dd56f124a5995b85e7a4dc22345 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
112 schema:name Antineoplastic Agents, Immunological
113 rdf:type schema:DefinedTerm
114 N85c85fd9deb54d078499aa209edc9727 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Aged
116 rdf:type schema:DefinedTerm
117 N91fd46c626024afbbc5cc8d9e04e8067 rdf:first sg:person.0767403115.48
118 rdf:rest N368b83474971493a9babf14adc5b7844
119 N95846e096d3845e59f110391cecc8188 schema:name nlm_unique_id
120 schema:value 8309335
121 rdf:type schema:PropertyValue
122 N99bd846e3a3040f9b7d13c804e927ac1 rdf:first sg:person.0664155437.21
123 rdf:rest N91fd46c626024afbbc5cc8d9e04e8067
124 Na936b8deaeba43b6b511d1adce7605ca rdf:first sg:person.014305467411.25
125 rdf:rest rdf:nil
126 Nabeca82624de4d11a42cd3abca735a7a schema:name pubmed_id
127 schema:value 27844311
128 rdf:type schema:PropertyValue
129 Nb20d5fed7e614ffbb6187dbd8b284b1d schema:volumeNumber 131
130 rdf:type schema:PublicationVolume
131 Nba3b3106819b4de5acf7b3083266fdc2 schema:name Springer Nature - SN SciGraph project
132 rdf:type schema:Organization
133 Nc043c3af1d83423bac39c0d8389ca4c0 schema:issueNumber 1
134 rdf:type schema:PublicationIssue
135 Nc5f4f955a8d04dc398e837b36d110f49 rdf:first sg:person.010336770753.05
136 rdf:rest Na936b8deaeba43b6b511d1adce7605ca
137 Ncd18a4907f854f8dbf043819a5ce14a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Young Adult
139 rdf:type schema:DefinedTerm
140 Nd14c08c66e61441aa6c0d1bf4ef830ab schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Disease-Free Survival
142 rdf:type schema:DefinedTerm
143 Ndf609ccb9c98467196d9035840a8023d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Antibodies, Monoclonal, Humanized
145 rdf:type schema:DefinedTerm
146 Nf4418c2cd2b74d5aafaee4428b4a9184 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Female
148 rdf:type schema:DefinedTerm
149 Nf45086036bce4b3f85cc6587c2d7be17 schema:name doi
150 schema:value 10.1007/s11060-016-2287-6
151 rdf:type schema:PropertyValue
152 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
153 schema:name Medical and Health Sciences
154 rdf:type schema:DefinedTerm
155 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
156 schema:name Clinical Sciences
157 rdf:type schema:DefinedTerm
158 sg:journal.1094205 schema:issn 0167-594X
159 1573-7373
160 schema:name Journal of Neuro-Oncology
161 rdf:type schema:Periodical
162 sg:person.010336770753.05 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
163 schema:familyName Nade
164 schema:givenName Minal
165 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010336770753.05
166 rdf:type schema:Person
167 sg:person.010544200534.01 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
168 schema:familyName Miday
169 schema:givenName Robert
170 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010544200534.01
171 rdf:type schema:Person
172 sg:person.010677556177.51 schema:affiliation https://www.grid.ac/institutes/grid.16753.36
173 schema:familyName Raizer
174 schema:givenName Jeffrey
175 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010677556177.51
176 rdf:type schema:Person
177 sg:person.01070375330.62 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
178 schema:familyName Canelos
179 schema:givenName Paola
180 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070375330.62
181 rdf:type schema:Person
182 sg:person.01326261166.36 schema:affiliation https://www.grid.ac/institutes/grid.34477.33
183 schema:familyName Chamberlain
184 schema:givenName Marc
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01326261166.36
186 rdf:type schema:Person
187 sg:person.01346246457.67 schema:affiliation https://www.grid.ac/institutes/grid.427785.b
188 schema:familyName Phuphanich
189 schema:givenName Surasak
190 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01346246457.67
191 rdf:type schema:Person
192 sg:person.014305467411.25 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
193 schema:familyName Laubscher
194 schema:givenName Kevin
195 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014305467411.25
196 rdf:type schema:Person
197 sg:person.0664155437.21 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
198 schema:familyName Narwal
199 schema:givenName Rajesh
200 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0664155437.21
201 rdf:type schema:Person
202 sg:person.0767403115.48 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
203 schema:familyName Hong
204 schema:givenName Shengyan
205 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0767403115.48
206 rdf:type schema:Person
207 sg:pub.10.1007/s00280-014-2567-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032526725
208 https://doi.org/10.1007/s00280-014-2567-9
209 rdf:type schema:CreativeWork
210 sg:pub.10.1007/s11060-009-9957-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040541619
211 https://doi.org/10.1007/s11060-009-9957-6
212 rdf:type schema:CreativeWork
213 sg:pub.10.1007/s11060-009-9976-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019029141
214 https://doi.org/10.1007/s11060-009-9976-3
215 rdf:type schema:CreativeWork
216 sg:pub.10.1038/sj.bjc.6605225 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030833831
217 https://doi.org/10.1038/sj.bjc.6605225
218 rdf:type schema:CreativeWork
219 sg:pub.10.1038/sj.bjc.6605411 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013740225
220 https://doi.org/10.1038/sj.bjc.6605411
221 rdf:type schema:CreativeWork
222 https://app.dimensions.ai/details/publication/pub.1075516477 schema:CreativeWork
223 https://app.dimensions.ai/details/publication/pub.1075562439 schema:CreativeWork
224 https://doi.org/10.1016/j.ctrv.2012.05.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001159071
225 rdf:type schema:CreativeWork
226 https://doi.org/10.1016/s1470-2045(09)70025-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002463620
227 rdf:type schema:CreativeWork
228 https://doi.org/10.1093/neuonc/not151 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003959313
229 rdf:type schema:CreativeWork
230 https://doi.org/10.1101/gad.1972310 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050112647
231 rdf:type schema:CreativeWork
232 https://doi.org/10.1124/mol.112.084079 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048097764
233 rdf:type schema:CreativeWork
234 https://doi.org/10.1158/2326-6066.cir-13-0028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004343764
235 rdf:type schema:CreativeWork
236 https://doi.org/10.1200/jco.1999.17.8.2572 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074549881
237 rdf:type schema:CreativeWork
238 https://doi.org/10.1200/jco.2008.19.8721 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042965400
239 rdf:type schema:CreativeWork
240 https://doi.org/10.1200/jco.2009.26.3541 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043187529
241 rdf:type schema:CreativeWork
242 https://doi.org/10.1212/wnl.0b013e31820f2d94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064355987
243 rdf:type schema:CreativeWork
244 https://doi.org/10.1371/journal.pone.0007752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018946723
245 rdf:type schema:CreativeWork
246 https://doi.org/10.3109/03009734.2014.970304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041806583
247 rdf:type schema:CreativeWork
248 https://doi.org/10.4161/mabs.3.2.14239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020539044
249 rdf:type schema:CreativeWork
250 https://www.grid.ac/institutes/grid.16753.36 schema:alternateName Northwestern University
251 schema:name Northwestern Brain Tumor Institute, Northwestern University, 675 N. St. Clair, 60611, Chicago, IL, USA
252 rdf:type schema:Organization
253 https://www.grid.ac/institutes/grid.34477.33 schema:alternateName University of Washington
254 schema:name University of Washington, 1959 NE Pacific St., 8th Floor, 98195, Seattle, WA, USA
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
257 schema:name MedImmune, 1 MedImmune Way, 20878, Gaithersburg, MD, USA
258 rdf:type schema:Organization
259 https://www.grid.ac/institutes/grid.427785.b schema:alternateName Barrow Neurological Institute
260 schema:name Department of Neurology, Division of Neuro-Oncology, Barrow Neurological Institute, 240 West Thomas Road, Suite 400, 85013, Phoenix, AZ, USA
261 Johnnie L. Cochran Jr. Brain Tumor Center, Cedars-Sinai Medical Center, 127 South San Vicente Blvd, Los Angeles, CA, USA
262 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...